Search

Author/Creator Hofmann, Carsten

11. O1‐09‐03: 24‐MONTH AMYLOID PET RESULTS OF THE GANTENERUMAB HIGH‐DOSE OPEN LABEL EXTENSION STUDIES. (1st July 2006)

Authors:
Klein, Gregory; Delmar, Paul; Hofmann, Carsten; Abi-Saab, Danielle; Andjelkovic, Mirjana; Ristic, Smiljana; Voyle, Nicola; Seibyl, John; Marek, Ken; Martenyi, Ferenc; Baudler, Monika; Fontoura, Paulo; Doody, Rachelle
Journal:
Alzheimer's & dementia
Issue:
Volume 14:Supplement 7S(2018)Part 4
Page Start:
P240
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

12. Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates. (6th November 2022)

Authors:
Ramakrishnan, Vidya; Friedrich, Christina; Witt, Colleen; Sheehan, Robert; Pryor, Meghan; Atwal, Jasvinder K.; Wildsmith, Kristin; Kudrycki, Katherine; Lee, Seung‐Hye; Mazer, Norman; Hofmann, Carsten; Fuji, Reina N.; Jin, Jin Y.; Ramanujan, Saroja; Dolton, Michael; Quartino, Angelica
Journal:
CPT: pharmacometrics & systems pharmacology
Issue:
Volume 12:Number 1(2023)
Page Start:
62
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

13. Why does ARIA‐E appear bright? A quantitative model linking brain tissue composition and T2 FLAIR hyperintensities: Neuroimaging / evaluating treatments. (7th December 2020)

Authors:
Aldea, Roxana; Grimm, Hans Peter; Gieschke, Ronald; Hofmann, Carsten; Klein, Gregory; Kunnecke, Basil; Piazza, Fabrizio; Carare, Roxana O; Mazer, Norman A
Journal:
Alzheimer's & dementia
Issue:
Volume 16(2020)Supplement 4
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗